This investment underscores industry interest in addressing the unmet needs of those living with, treating, and researching MS. "We look forward to working with the team as they continue to craft their platform focused on multi-modality, integrated findings and expanded disease insights." Rubin, Ph.D., Managing Director of Merck GHIF. "Octave’s approach to improve patient outcomes in multiple sclerosis is powerful and we believe will have broader neurodegenerative disease applications," said David M. We believe that this is just the beginning of a long and productive relationship that can help us shift the paradigm for patients with MS and a broad range of neurodegenerative diseases."
#Octave bioscience full#
"This investment further expands our already broad syndicate and further enables the full breadth of Octave’s services, ranging from measurement and management tools for physicians as they manage their patients to a precision-based set of tools and services that can help pharmaceutical companies better characterize their therapies and reveal additional insight to optimize their pipeline programs. "The investment from Merck GHIF is a testament to the strength of our strategy, our team, technologies and platform," said William Hagstrom, Chief Executive Officer and Founder of Octave. Octave Bioscience, the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund ( Merck GHIF) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases. OCTAVE BIOSCIENCE ANNOUNCES STRATEGIC INVESTMENT FROM THE MERCK GLOBAL HEALTH INNOVATION FUND TO TRANSFORM DISEASE MEASUREMENT AND CARE FOR PATIENTS WITH NEURODEGENERATIVE DISEASES & KENILWORTH, N.J., October 11, 2021-( BUSINESS WIRE)-Fifth paragraph of the release should read: For more information, please visit and (instead of For more information, please visit and The updated release reads: The subject of this webinar was to review the research, development and validation of the custom assay panel.Octave to establish a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights for neurodegenerative diseases The 21-plex panel has been manufactured and analytically validated in preparation for a forthcoming clinical validation in independent cohorts. A dynamic and iterative process that balanced statistical, analytical, and biological factors was then used to select proteins for inclusion in the custom panel. The development of this panel involved screening over 1000 protein biomarkers in several deeply phenotyped studies.
![octave bioscience octave bioscience](https://i1.sndcdn.com/artworks-bEOx12Udxy875I1i-exiRhw-t500x500.jpg)
Octave Bioscience has developed an integrated Care Platform that consists of several tools to improve measurement capabilities in MS, including a custom assay panel performed using the Olink Platform to quantitatively assess the level of disease activity in blood samples. Speaker: Ferhan Qureshi, Vice President – Biomarker Product DevelopmentĬare for Multiple Sclerosis patients relies heavily on assessments that are subjective, qualitative and inadequate. Original broadcast date: Thursday, 01 April 2021 Listen to the power of Olink's scalability from the customer perspective